Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AUTL | US
0.12
3.15%
Healthcare
Biotechnology
30/06/2024
30/08/2024
3.93
3.85
3.94
3.80
Autolus Therapeutics plc a clinical-stage biopharmaceutical company develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1) a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22 which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4 a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG a programmed T cell investigational therapy which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8 a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5 a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London the United Kingdom.
View LessValue Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
36.3%1 month
61.3%3 months
63.4%6 months
62.1%-
-
2.01
-
-
0.03
38.66
-
-186.21M
1.05B
1.05B
-
-1.84K
-
681.00
-61.80
9.49
6.30
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.47
Range1M
1.28
Range3M
1.71
Rel. volume
0.49
Price X volume
1.37M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AnaptysBio Inc | ANAB | Biotechnology | 38.09 | 1.15B | 4.01% | n/a | 0.00% |
immatics biotechnologies GmbH | IMTX | Biotechnology | 11.09 | 1.14B | 0.09% | n/a | 0.00% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 16.52 | 1.13B | 1.35% | n/a | 0.00% |
Calliditas Therapeutics AB | CALT | Biotechnology | 40.12 | 1.08B | -0.99% | n/a | 0.00% |
Xencor Inc | XNCR | Biotechnology | 17.49 | 1.08B | 1.04% | n/a | 15.54% |
ELVN | ELVN | Biotechnology | 21.88 | 1.03B | -1.53% | n/a | 0.00% |
Tarsus Pharmaceuticals Inc | TARS | Biotechnology | 27.11 | 1.03B | -1.78% | n/a | 0.00% |
Array BioPharma Inc | ARRY | Biotechnology | 6.71 | 1.02B | -2.04% | 69.20 | 0.00% |
89bio Inc | ETNB | Biotechnology | 9.5 | 1.01B | 2.93% | n/a | 0.00% |
CARGO Therapeutics Inc. Common Stock | CRGX | Biotechnology | 18.86 | 988.84M | 6.01% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Camping World Holdings Inc | CWH | Recreational Vehicles | 21.94 | 990.13M | 0.14% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 36.37 | 743.39M | 4.66% | n/a | 4.21% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.25 | 722.36M | 0.32% | 59.09 | 0.00% |
Ennis Inc | EBF | Building Products & Equipment | 23.91 | 621.28M | 1.18% | 14.56 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.45 | 391.86M | -0.16% | 50.52 | 0.00% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 24.03 | 385.84M | 0.33% | n/a | 0.00% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.4 | 326.35M | 0.00% | 12.84 | 0.00% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 28.64 | 316.93M | -0.52% | 18.51 | -621.78% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 18.53 | 314.66M | -0.70% | 8.90 | 25.57% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.03 | 1.02 | Cheaper |
Ent. to Revenue | 38.66 | 3,693.42 | Cheaper |
PE Ratio | - | 40.05 | - |
Price to Book | 2.01 | 14.24 | Cheaper |
Dividend Yield | - | 2.25 | - |
Std. Deviation (3M) | 63.44 | 77.16 | Par |
Debt to Equity | - | -5.69 | - |
Debt to Assets | - | 0.24 | - |
Market Cap | 1.05B | 4.06B | Emerging |